Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten JM, et al. N Engl J Med. 2012;367(5):399-410.
Twice-yearly lenacapavir or Daily F/TAF for HIV prevention in cisgender women.
Bekker LG, Das M, Abdool Karim Q, et al. N Engl J Med. 2024 [Epub ahead of print]
Issue brief: status neutral HIV care and service delivery.
CDC.
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant RM, Lama JR, Anderson PL, et al. N Engl J Med. 2010;363(27):2587-2599.
Global LGBTQ Health.
Hwahng SJ, Kaufman MR, eds. Florida State University; Springer, 2024.
Cabotegravir for HIV prevention in cisgender men and transgender women.
Landovitz RJ, Donnell D, Clement ME, et al. N Engl J Med. 2021;385(7):595-608.
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Mayer KH, Molina JM, Thompson MA, et al. Lancet. 2020;396(10246):239-254.
Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review.
Palacio-Vieira J, Reyes-Urueña JM, Imaz A, et al. BMC Public Health. 2021;21(1):1596.
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study.
Rodger AJ, Cambiano V, Bruun T, et al. Lancet. 2019;393(10189):2428-2438.
SAMHSA’s Concept of Trauma and Guidance for a Trauma-Informed Approach.
Substance Abuse and Mental Health Services Administration (SAMHSA). HHS Publication No. (SMA) 14-4884. Rockville, MD: SAMHSA 2014.
Identifying the barriers and facilitators to culturally responsive HIV and PrEP screening for racial, ethnic, sexual, and gender minoritized patients: a scoping review protocol.
Xavier J, Ward MC, Corr PG, et al. PLoS One. 2023;18(5):e0281173.
DOWNLOADABLE RESOURCES
PrEP Clinician Reference Guide
HIV Treatment Clinician Reference Guide
CLINICAL PRACTICE GUIDELINES
STI and HIV infection risk assessment.
Centers for Disease Control and Prevention (CDC).
Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society–USA Panel.
Gandhi RT, Bedimo R, Hoy JF, et al. JAMA. 2023;329(1):63-84.
Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV.
US Department of Health and Human Services.
Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update). A clinical practice guideline.
US Public Health Service. Centers for Disease Control and Prevention; 2021.
Final Recommendation Statement. Prevention of Acquisition of HIV: Preexposure Prophylaxis.
U.S. Preventive Services Task Force. 2023.
CLINICIAN RESOURCES
Immediate ART initiation & restart: guide for clinicians.
AIDS Education and Training Center Program.
Clinical Guidelines Program: HIV treatment
New York State Department of Health AIDS Institute
National Clinician Consultation Center.
University of California, San Francisco.
Published recommendations.
US Preventive Services Task Force.